What you'll actually pay per month for tirzepatide in 2026 — across compounded and brand-name routes — and the three factors that move the number.
Your monthly cost depends almost entirely on the route: brand-name vs compounded, and which self-pay program you use. Compounded is cash-pay and not FDA-approved; brand-name is FDA-approved.
| Option | Type | From / month | FDA status |
|---|---|---|---|
| NexLife Editor's pick | Compounded | $186/mo* | Not FDA-approved |
| Other compounded programs | Compounded | $209–$400/mo | Not FDA-approved |
| Zepbound® LillyDirect (Self Pay Journey) | Brand | $299–$449/mo | FDA-approved |
| Zepbound® retail (KwikPen list) | Brand | ~$1,086/mo | FDA-approved |
| Mounjaro® retail (T2D) | Brand | $1,069–$1,080/mo | FDA-approved |
*NexLife flat 12-month plan; the per-month price is the same at every dose. Multi-month plans price lower per month ($190 6-mo · $195 3-mo · $215 monthly).
Three things move the monthly number: (1) brand vs compounded, (2) your plan term — longer commitments lower the per-month rate, and (3) for brand-name, whether you stay inside LillyDirect's 45-day refill window. With flat compounded pricing, the monthly figure doesn't change as you titrate. See the price-by-dose breakdown and maintenance cost.
Compounded tirzepatide is cash-pay from about $186/month flat; brand-name Zepbound runs $299–$449/month via LillyDirect's Self Pay Journey Program or ~$1,086 at retail. Compounded is not FDA-approved. See NexLife pricing
With flat-rate compounded pricing it does not. Some programs and brand self-pay tiers do increase with dose — see our price-by-dose guide.
No. Compounded tirzepatide is not FDA-approved. Only brand-name Mounjaro (type 2 diabetes) and Zepbound (chronic weight management), made by Eli Lilly, are FDA-approved. Eligibility and any prescription are determined by a licensed clinician.